Findings from the APPEAR-C3G trial showed a 35% reduction in 24-hour UPCR from baseline (primary endpoint) in the iptacopan group compared with the placebo group. The Food and Drug Administration ...

The primary endpoint was the percent reduction in UPCR (sampled from a 24-hr urine collection) at week 36 compared with baseline. The efficacy analysis was based on the first 270 patients in the ...